Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2026

Facchinetti Francesco, Hollebecque Antoine, Barbé Rémy, Jang Dong Man, Alonso-De-Castro Beatriz, Brayé Floriane, Bigot Ludovic, Nobre Catline, Da Silva Alice, Méteau Mélissandre, Delavigne Mathis, Soares Miguel, Italiano Antoine, Rodriguez Julieta, Mosele Fernanda, Beshiri Kristi, Ducreux Michel, Boilève Alice, Nikolaev Sergey, Alonso-Garcia Inmaculada, Vasseur Damien, Smolenschi Cristina, Bourien Héloise, Cotteret Sophie, Samaniego Juliette, Bernard Elsa, Nicotra Claudio, Ngo-Camus Maud, Nakazawa Seshiru, Tselikas Lambros, Badoual Cécile, André Fabrice, Eck Michael J, Olaussen Ken A, Loriot Yohann, Friboulet Luc

Abstract excerpt

PURPOSE: The use of reversible fibroblast growth factor receptor 2 (FGFR) inhibitors leads to the emergence of "undruggable" FGFR2 kinase domain mutations, hampering sequential treatment strategies. Lirafugratinib and futibatinib are irreversible FGFR inhibitors with the most promising clinical activity against FGFR2-driven tumors. EXPERIMENTAL DESIGN: We characterized resistance to lirafugratinib with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Exome Sequencing

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Share to Pyrroles

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 41632446
DOI: 10.1158/1078-0432.CCR-25-4390
PMCID: PMC13080319

Genes

FGFR2
BICC1
F3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.PMID 41632446Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.Semantic proximity Read ↗

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read ↗

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.Semantic proximity Read ↗

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.Semantic proximity Read ↗

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Semantic proximity Read ↗

Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.Semantic proximity Read ↗

The evolving role of futibatinib for advanced cholangiocarcinoma.Semantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

Integrative Proteogenomic and Single-Cell Analysis Reveals RTK Switching and Metabolic Reprogramming as Synthetic Lethal Vulnerabilities in FGFR Inhibitor ResistanceSemantic proximity Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.